List view / Grid view

Faron Pharmaceuticals Ltd

 

news

Faron announces intention to float on AIM

7 September 2015 | By Victoria White

Faron's admission to AIM will support development of its lead candidate, Traumakine, into a Phase III Study and the development of its preclinical cancer immunotherapy candidate, Clevegen...